Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa Palmer

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Hepatology (Baltimore, Md.)|August 14, 2012
Practice guidelines on NAFLDMelissa Palmer
Sex Education|March 5, 2019
Birth order and parental and sibling involvement in sex education. A nationally-representative analysisLotte Elton, Melissa Palmer, Wendy Macdowall
The Journal of General Physiology|November 27, 2002
UTP-dependent inhibition of Na+ absorption requires activation of PKC in endometrial epithelial cellsMelissa Palmer-Densmore, Chatsri Deachapunya, Mathur Kannan, et al.
Sexual and Reproductive Health Matters|June 17, 2022
The impact of COVID-19 lockdown on abortion care: a time series analysis of data from Marie Stopes NepalCorrina Horan, Melissa Palmer, Raman Shrestha, et al.
BMC Pharmacology & Toxicology|March 18, 2018
A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitisMelissa Palmer, Lee Jennings, Debra G Silberg, et al.
Clinical Trials (London, England)|March 7, 2022
A dynamic and collaborative approach to trial recruitment in safetxt, a UK sexual health randomised controlled trialLauren Jerome, Kimberley Potter, Ona McCarthy, et al.
Plos One|June 25, 2019
Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden miceKanita Salic, Robert Kleemann, Cynthia Wilkins-Port, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|August 11, 2025
Preference for Face-to-Face Contraceptive Service Delivery Post-COVID-19 Pandemic: A Cross-Sectional StudySophie Patterson, Nicola Rennie, Sue Mann, et al.
The Mental Health Clinician|June 30, 2018
Review of pharmacologic treatment in cluster A personality disordersJessa Koch, Taylor Modesitt, Melissa Palmer, et al.
European Journal of Drug Metabolism and Pharmacokinetics|July 14, 2017
Absorption, Distribution, Metabolism, and Excretion of [<sup>14</sup>C]-Volixibat in Healthy Men: Phase 1 Open-Label StudyNicholas Siebers, Melissa Palmer, Debra G Silberg, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Hepatology (Baltimore, Md.)|August 14, 2012
Practice guidelines on NAFLDMelissa Palmer
Sex Education|March 5, 2019
Birth order and parental and sibling involvement in sex education. A nationally-representative analysisLotte Elton, Melissa Palmer, Wendy Macdowall
The Journal of General Physiology|November 27, 2002
UTP-dependent inhibition of Na+ absorption requires activation of PKC in endometrial epithelial cellsMelissa Palmer-Densmore, Chatsri Deachapunya, Mathur Kannan, et al.
Sexual and Reproductive Health Matters|June 17, 2022
The impact of COVID-19 lockdown on abortion care: a time series analysis of data from Marie Stopes NepalCorrina Horan, Melissa Palmer, Raman Shrestha, et al.
BMC Pharmacology & Toxicology|March 18, 2018
A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitisMelissa Palmer, Lee Jennings, Debra G Silberg, et al.
Clinical Trials (London, England)|March 7, 2022
A dynamic and collaborative approach to trial recruitment in safetxt, a UK sexual health randomised controlled trialLauren Jerome, Kimberley Potter, Ona McCarthy, et al.
Plos One|June 25, 2019
Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden miceKanita Salic, Robert Kleemann, Cynthia Wilkins-Port, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|August 11, 2025
Preference for Face-to-Face Contraceptive Service Delivery Post-COVID-19 Pandemic: A Cross-Sectional StudySophie Patterson, Nicola Rennie, Sue Mann, et al.
The Mental Health Clinician|June 30, 2018
Review of pharmacologic treatment in cluster A personality disordersJessa Koch, Taylor Modesitt, Melissa Palmer, et al.
European Journal of Drug Metabolism and Pharmacokinetics|July 14, 2017
Absorption, Distribution, Metabolism, and Excretion of [<sup>14</sup>C]-Volixibat in Healthy Men: Phase 1 Open-Label StudyNicholas Siebers, Melissa Palmer, Debra G Silberg, et al.
Pageof 5